Literature DB >> 14657387

Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production.

Vasundhara Varthakavi1, Rita M Smith, Stephan P Bour, Klaus Strebel, Paul Spearman.   

Abstract

Human cells resist viral infections by a variety of mechanisms. Viruses must overcome host cell restrictions to successfully reproduce their genetic material. Here, we identify a host restriction to viral replication that acts at the stage of particle assembly. Viral protein U (Vpu) is an HIV-1 accessory protein that enhances particle assembly and release in most human cells, but not in simian cells. By using human-simian cell heterokaryons, we show that the inhibition of assembly in human cells is dominant. Vpu overcomes the block to assembly in human cells and in human-simian heterokaryons. The HIV-1 vpu gene may have evolved to counteract an assembly restriction that is present in human cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14657387      PMCID: PMC299932          DOI: 10.1073/pnas.2433165100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Function of human immunodeficiency virus type 1 Vpu protein in various cell types.

Authors:  H Sakai; K Tokunaga; M Kawamura; A Adachi
Journal:  J Gen Virol       Date:  1995-11       Impact factor: 3.891

2.  Multiple copies of the Mason-Pfizer monkey virus constitutive RNA transport element lead to enhanced HIV-1 Gag expression in a context-dependent manner.

Authors:  H Wodrich; A Schambach; H G Kräusslich
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

3.  The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

Authors:  Y Huang; W A Paxton; S M Wolinsky; A U Neumann; L Zhang; T He; S Kang; D Ceradini; Z Jin; K Yazdanbakhsh; K Kunstman; D Erickson; E Dragon; N R Landau; J Phair; D D Ho; R A Koup
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

4.  The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation.

Authors:  S Bour; U Schubert; K Strebel
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

Review 5.  Generation of high-titer pseudotyped retroviral vectors with very broad host range.

Authors:  J K Yee; T Friedmann; J C Burns
Journal:  Methods Cell Biol       Date:  1994       Impact factor: 1.441

6.  The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses.

Authors:  R K Naviaux; E Costanzi; M Haas; I M Verma
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses.

Authors:  S Bour; K Strebel
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

8.  The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?

Authors:  S Bour; U Schubert; K Peden; K Strebel
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

9.  The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains.

Authors:  U Schubert; S Bour; A V Ferrer-Montiel; M Montal; F Maldarell; K Strebel
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes.

Authors:  U Schubert; K A Clouse; K Strebel
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more
  106 in total

1.  Controlling lentiviruses: single amino acid changes can determine specificity.

Authors:  Shari M Kaiser; Michael Emerman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-09       Impact factor: 11.205

2.  Oligomerization state and supramolecular structure of the HIV-1 Vpu protein transmembrane segment in phospholipid bilayers.

Authors:  Jun-Xia Lu; Simon Sharpe; Rodolfo Ghirlando; Wai-Ming Yau; Robert Tycko
Journal:  Protein Sci       Date:  2010-10       Impact factor: 6.725

Review 3.  Ion channels as antivirus targets.

Authors:  Xin Liang; Zhi-Yuan Li
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

Review 4.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  HIV accessory proteins and surviving the host cell.

Authors:  Jenny L Anderson; Thomas J Hope
Journal:  Curr HIV/AIDS Rep       Date:  2004-04       Impact factor: 5.071

6.  The retroviral restriction factor TRIM5alpha.

Authors:  Sarah Sebastian; Jeremy Luban
Journal:  Curr Infect Dis Rep       Date:  2007-03       Impact factor: 3.725

7.  Conformational changes induced by a single amino acid substitution in the trans-membrane domain of Vpu: implications for HIV-1 susceptibility to channel blocking drugs.

Authors:  Sang Ho Park; Stanley J Opella
Journal:  Protein Sci       Date:  2007-08-31       Impact factor: 6.725

8.  Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant.

Authors:  Chisu Song; Christopher Aiken
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.

Authors:  Janet L Douglas; Ying Bai; Jean K Gustin; Ashlee V Moses
Journal:  Virology       Date:  2013-04-10       Impact factor: 3.616

10.  Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.

Authors:  Janet L Douglas; Kasinath Viswanathan; Matthew N McCarroll; Jean K Gustin; Klaus Früh; Ashlee V Moses
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.